• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无细胞浓缩腹水回输治疗的合适流速设置及腹水中细胞因子浓度变化的研究

A study of appropriate flow rate settings for cell-free and concentrated ascites reinfusion therapy and change of cytokine concentrations in ascites.

作者信息

Orimi Syouji, Mizuno Katsunari, Narahara Michihito, Umakosi Hideko, Kaihara Masanori, Hashimoto Masami

机构信息

Medical Engineering Center, Onomichi Municipal Hospital, Onimichi, Hiroshima, Japan.

出版信息

Ther Apher Dial. 2011 Aug;15(4):411-4. doi: 10.1111/j.1744-9987.2011.00973.x.

DOI:10.1111/j.1744-9987.2011.00973.x
PMID:21884478
Abstract

We examined appropriate flow rates for high collection rates of Total Protein (TP) and Albumin (Alb) and a change of IL-6 concentrations in the cell-free and concentrated ascites reinfusion therapy (CART) process. No significant changes were observed in IL-6 concentration in the ascites storage test and the circulatory stimulation test. However, it was confirmed that the quantity of IL-6 in the ascites decreased by means of filtration and concentration. In some cases, it quickly reached high concentration rates at a higher flow rate (200 mL/min) setting, but clogging or pressure increase has occurred in the hollow fiber filter. Therefore, it was concluded that a low flow rate (50 mL/min) setting was best and provides safer conditions for filtration and concentration in order to collect TP and Alb effectively and reuse it as autologous protein, which is the primary objective of CART.

摘要

我们研究了在无细胞浓缩腹水再输注疗法(CART)过程中,实现总蛋白(TP)和白蛋白(Alb)高收集率以及白细胞介素-6(IL-6)浓度变化的合适流速。在腹水储存试验和循环刺激试验中,未观察到IL-6浓度有显著变化。然而,经证实,通过过滤和浓缩,腹水中IL-6的量减少了。在某些情况下,在较高流速(200 mL/分钟)设置下能迅速达到高浓缩率,但中空纤维滤器出现了堵塞或压力增加的情况。因此,得出的结论是,低流速(50 mL/分钟)设置最佳,可为过滤和浓缩提供更安全的条件,以便有效收集TP和Alb并将其作为自体蛋白重复使用,这是CART的主要目标。

相似文献

1
A study of appropriate flow rate settings for cell-free and concentrated ascites reinfusion therapy and change of cytokine concentrations in ascites.无细胞浓缩腹水回输治疗的合适流速设置及腹水中细胞因子浓度变化的研究
Ther Apher Dial. 2011 Aug;15(4):411-4. doi: 10.1111/j.1744-9987.2011.00973.x.
2
Characteristics of Patients and Their Ascites Who Underwent Repeated Cell-Free and Concentrated Ascites Reinfusion Therapy.接受重复无细胞浓缩腹水回输治疗的患者及其腹水的特征。
Ther Apher Dial. 2015 Aug;19(4):342-8. doi: 10.1111/1744-9987.12343.
3
Ascitic IL-10 Concentration Predicts Prognosis of Patients Undergoing Cell-Free and Concentrated Ascites Reinfusion Therapy.腹水白细胞介素-10浓度可预测接受无细胞浓缩腹水回输治疗患者的预后。
Ther Apher Dial. 2020 Feb;24(1):90-95. doi: 10.1111/1744-9987.12863. Epub 2019 Aug 6.
4
Single center experience of cell-free and concentrated ascites reinfusion therapy in malignancy related ascites.无细胞浓缩腹水回输疗法治疗恶性肿瘤相关性腹水的单中心经验
Ther Apher Dial. 2014 Feb;18(1):87-92. doi: 10.1111/1744-9987.12049. Epub 2013 Apr 17.
5
[Cell-free and concentrated ascites reinfusion therapy(CART)].[无细胞浓缩腹水回输疗法(CART)]
Gan To Kagaku Ryoho. 2012 Dec;39 Suppl 1:33-5.
6
Cell-Free and Concentrated Ascites Reinfusion Therapy for Decompensated Liver Cirrhosis.无细胞浓缩腹水回输疗法治疗失代偿期肝硬化
Ther Apher Dial. 2016 Aug;20(4):376-82. doi: 10.1111/1744-9987.12469.
7
Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study.浓缩腹水再回输治疗恶性腹水的疗效和安全性:概念验证研究。
Support Care Cancer. 2018 May;26(5):1489-1497. doi: 10.1007/s00520-017-3980-5. Epub 2017 Nov 22.
8
Concentrated ascites reinfusion therapy for sinusoidal obstructive syndrome after hematopoietic stem cell transplantation.浓缩腹水回输治疗造血干细胞移植后肝窦阻塞综合征。
Artif Organs. 2013 Oct;37(10):932-6. doi: 10.1111/aor.12080. Epub 2013 May 20.
9
Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites.一项前瞻性研究,比较人血白蛋白与在肝硬化合并顽固性腹水患者进行完全腹腔穿刺放液后回输超滤后的腹水。
Z Gastroenterol. 2001 Jan;39(1):5-10. doi: 10.1055/s-2001-10707.
10
Ultrastructural observation of filtration membrane in cell-free and concentrated ascites reinfusion therapy for malignant ascites.无细胞浓缩腹水回输治疗恶性腹水滤过膜的超微结构观察。
Ther Apher Dial. 2022 Jun;26(3):649-657. doi: 10.1111/1744-9987.13747. Epub 2021 Oct 28.

引用本文的文献

1
Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in Japan.日本一项回顾性观察研究:无细胞浓缩腹水回输治疗肝硬化难治性腹水患者凝血和纤溶因子的变化。
In Vivo. 2023 May-Jun;37(3):1226-1235. doi: 10.21873/invivo.13199.
2
Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy.内毒素活性反映了行无细胞浓缩腹水回输治疗的肝硬化腹水患者体温升高。
In Vivo. 2022 May-Jun;36(3):1477-1484. doi: 10.21873/invivo.12854.
3
Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience.
无细胞浓缩腹水回输治疗恶性腹水的不良反应:单中心经验。
BMC Cancer. 2022 Mar 14;22(1):268. doi: 10.1186/s12885-022-09298-6.
4
Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients: a retrospective controlled cohort study.血清白蛋白升高效应的验证——细胞游离浓缩腹水再输注疗法治疗腹水患者:一项回顾性对照队列研究。
Sci Rep. 2019 Jul 15;9(1):10195. doi: 10.1038/s41598-019-46774-9.
5
Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites.腹水游离细胞浓缩再回输疗法在大量腹水的晚期卵巢癌患者治疗管理中的应用。
Int J Clin Oncol. 2019 Apr;24(4):420-427. doi: 10.1007/s10147-018-1371-7. Epub 2018 Nov 24.
6
Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study.浓缩腹水再回输治疗恶性腹水的疗效和安全性:概念验证研究。
Support Care Cancer. 2018 May;26(5):1489-1497. doi: 10.1007/s00520-017-3980-5. Epub 2017 Nov 22.
7
Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.无细胞浓缩腹水回输疗法(CART)治疗难治性腹水的安全性和有效性:上市后监测结果。
PLoS One. 2017 May 16;12(5):e0177303. doi: 10.1371/journal.pone.0177303. eCollection 2017.
8
Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer.重复无细胞浓缩腹水回输治疗胃肠道癌恶性腹水的安全性
Mol Clin Oncol. 2014 Nov;2(6):1103-1106. doi: 10.3892/mco.2014.335. Epub 2014 Jul 4.